Incyte Corp. (NASDAQ:INCY) EVP Barry P. Flannelly sold 24,204 shares of the business’s stock in a transaction that occurred on Friday, October 7th. The stock was sold at an average price of $97.00, for a total value of $2,347,788.00. Following the transaction, the executive vice president now owns 13,595 shares in the company, valued at $1,318,715. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Incyte Corp. (NASDAQ:INCY) opened at 89.97 on Thursday. The firm has a 50-day moving average of $86.48 and a 200 day moving average of $81.39. Incyte Corp. has a 1-year low of $55.00 and a 1-year high of $124.98. The firm has a market cap of $16.91 billion, a P/E ratio of 244.48 and a beta of 0.54.

Incyte Corp. (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.20. Incyte Corp. had a net margin of 7.87% and a return on equity of 37.76%. The firm had revenue of $208 million for the quarter, compared to the consensus estimate of $236.91 million. During the same quarter in the previous year, the firm posted $0.05 EPS. The firm’s quarterly revenue was up 51.1% on a year-over-year basis. On average, analysts predict that Incyte Corp. will post $0.19 EPS for the current year.

Insider Buying and Selling by Quarter for Incyte Corp. (NASDAQ:INCY)

INCY has been the topic of several analyst reports. Zacks Investment Research lowered shares of Incyte Corp. from a “buy” rating to a “hold” rating in a research report on Tuesday, August 16th. RBC Capital Markets reaffirmed an “outperform” rating and set a $116.00 price target on shares of Incyte Corp. in a research report on Wednesday, September 28th. Argus lifted their price target on shares of Incyte Corp. from $92.00 to $98.00 and gave the company a “buy” rating in a research report on Monday, September 26th. SunTrust Banks Inc. initiated coverage on shares of Incyte Corp. in a research report on Friday, August 5th. They set a “buy” rating and a $105.00 price target on the stock. Finally, JMP Securities lifted their price target on shares of Incyte Corp. from $100.00 to $110.00 and gave the company a “market outperform” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twenty-one have assigned a buy rating to the company’s stock. Incyte Corp. has an average rating of “Buy” and a consensus price target of $105.79.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Incyte Corp. by 2.9% in the second quarter. Vanguard Group Inc. now owns 11,973,101 shares of the biopharmaceutical company’s stock valued at $957,608,000 after buying an additional 340,717 shares in the last quarter. Capital World Investors raised its position in shares of Incyte Corp. by 1.3% in the second quarter. Capital World Investors now owns 10,686,491 shares of the biopharmaceutical company’s stock valued at $854,706,000 after buying an additional 134,000 shares in the last quarter. Capital International Investors raised its position in shares of Incyte Corp. by 9.2% in the second quarter. Capital International Investors now owns 5,918,033 shares of the biopharmaceutical company’s stock valued at $473,324,000 after buying an additional 499,536 shares in the last quarter. FMR LLC raised its position in shares of Incyte Corp. by 2.1% in the second quarter. FMR LLC now owns 4,971,659 shares of the biopharmaceutical company’s stock valued at $397,633,000 after buying an additional 100,334 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its position in shares of Incyte Corp. by 5.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 4,143,431 shares of the biopharmaceutical company’s stock valued at $331,392,000 after buying an additional 207,712 shares in the last quarter. 92.32% of the stock is owned by institutional investors.

About Incyte Corp.

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).

5 Day Chart for NASDAQ:INCY

Receive News & Stock Ratings for Incyte Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corp. and related stocks with our FREE daily email newsletter.